Tokio Marine Asset Management Co. Ltd. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 158,076 shares of the biopharmaceutical company’s stock after acquiring an additional 3,557 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Pfizer were worth $4,194,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Wells Trecaso Financial Group LLC raised its position in Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 350 shares in the last quarter. Washington Trust Advisors Inc. raised its holdings in shares of Pfizer by 0.7% in the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after acquiring an additional 360 shares in the last quarter. PSI Advisors LLC lifted its stake in Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 385 shares during the period. Western Pacific Wealth Management LP grew its holdings in Pfizer by 10.5% during the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 386 shares in the last quarter. Finally, Waddell & Associates LLC increased its position in Pfizer by 1.6% during the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 388 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on PFE shares. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 1.5 %

NYSE PFE opened at $26.51 on Monday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a fifty day simple moving average of $26.27 and a two-hundred day simple moving average of $27.86. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.